Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 8/20 | 0.40 |
| ▸ | NAALAD2 | Q9Y3Q0 | 5/20 | 0.40 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.40 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | GGH | Q92820 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4653834 | 0.89 | GAA (0.42) | GAAFOLH1NAALAD2RIMKLATMPRSS15 | |
| SCHEMBL4652873 | 0.89 | GAA (0.42) | GAAFOLH1NAALAD2RIMKLATMPRSS15 | |
| SCHEMBL4161725 | 0.88 | GAA (0.41) | GAAFOLH1NAALAD2RIMKLATMPRSS15 | |
| SCHEMBL7902705 | 0.88 | LMNA (0.49) | GAAFOLH1NAALAD2RIMKLATMPRSS15 | |
| SCHEMBL4469539 | 0.88 | LMNA (0.49) | GAAFOLH1NAALAD2RIMKLATMPRSS15 | |
| SCHEMBL4652770 | 0.88 | GAA (0.41) | GAAFOLH1NAALAD2RIMKLATMPRSS15 | |
| SCHEMBL4652866 | 0.86 | GAA (0.40) | GAAFOLH1NAALAD2RIMKLATMPRSS15 | |
| SCHEMBL4652743 | 0.86 | GAA (0.40) | GAAFOLH1NAALAD2RIMKLATMPRSS15 | |
| SCHEMBL4652731 | 0.82 | CA2 (0.40) | GAAFOLH1NAALAD2RIMKLATMPRSS15 | |
| SCHEMBL4652733 | 0.82 | CA2 (0.40) | GAAFOLH1NAALAD2RIMKLATMPRSS15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6277880-B1 | ANTIBODY DIRECTED ENZYME PRODUG THERAPY | ZENECA LIMITED (GB) | 2001-08-21 | — | — | US | disclosed |
| US-5958971-A | PRODRUGS OF NITROGEN MUSTARD, AN ANTICARCINOGENIC AND TUMOR AGENT; ANTIBODY DIRECTED ENZYME PRODRUG THERAPY (ADEPT); BIOCHEMICAL CONJUGATION | ZENECA LIMITED (GB) | 1999-09-28 | — | — | US | disclosed |
| US-5714148-A | PRODRUGS WHICH ARE SUBSTRATES FOR CARBOXYPEPTIDASE G2 AND YIELD ACTIVE CYTOTOXIC DRUGS | ZENECA LIMITED (GB) | 1998-02-03 | — | — | US | disclosed |
| US-5660829-A | DEESTERIFYING COMPOUND TO FORM N-(4(N,N-BIS(2-CHLOROETHYL) AMINO)PHENOXYCARBONYL)-L-GLUTAMIC ACID-GAMMA-(3,5-DICARBOXY)ANILIDE | ZENECA LIMITED (GB) | 1997-08-26 | — | — | US | disclosed |
| US-5587161-A | TWO COMPONENT SYSTEM INCLUDING ANTIBODY OR ANTIGEN BINDING FRAGMENT CONJUGATED TO CARBOXYPEPTIDASE G ENZYME, COMPOUND CONVERTIBLE TO CYTOTOXIC DRUG UNDER INFLUENCE OF ENZYME | ZENECA LIMITED (GB) | 1996-12-24 | — | — | US | disclosed |
| EP-0651740-A1 | AMINO ACID LINKED NITROGEN MUSTARD DERIVATIVES AND THEIR USE AS PRODRUGS IN THE TREATMENT OF TUMOURS | ZENECA LIMITED (GB) | 1995-05-10 | — | — | EP | disclosed |
| US-5405990-A | For use in antibody directed enzyme prodrug therapy; cytotoxic parent nitrogen mustard; antitumor agents | ZENECA LIMITED (GB) | 1995-04-11 | — | — | US | disclosed |
| WO-1994002450-A1 | AMINO ACID LINKED NITROGEN MUSTARD DERIVATIVES AND THEIR USE AS PRODRUGS IN THE TREATMENT OF TUMOURS | ZENECA LIMITED (GB) | 1994-02-03 | — | — | WO | disclosed |